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Abstract
The interaction between leukocyte function-associated antigen-1(LFA-1) and intercellular adhesion molecule-1 (ICAM-1)
plays a pivotal role in cellular adhesion including the extravasation and inflammatory response of leukocytes, and also in the
formation of immunological synapse. However, irregular expressions of LFA-1 or ICAM-1 or both may lead to autoimmune
diseases, metastasis cancer, etc. Thus, the LFA-1/ICAM-1 interaction may serve as a potential therapeutic target for the
treatment of these diseases. Here, we developed one simple ‘in solution’ steady state fluorescence resonance energy
transfer (FRET) technique to obtain the dissociation constant (Kd) of the interaction between LFA-1 and ICAM-1. Moreover,
we developed the assay into a screening platform to identify peptides and small molecules that inhibit the LFA-1/ICAM-1
interaction. For the FRET pair, we used Alexa Fluor 488-LFA-1 conjugate as donor and Alexa Fluor 555-human recombinant
ICAM-1 (D1-D2-Fc) as acceptor. From our quantitative FRET analysis, the Kd between LFA-1 and D1-D2-Fc was determined to
be 17.9361.34 nM. Both the Kd determination and screening assay were performed in a 96-well plate platform, providing
the opportunity to develop it into a high-throughput assay. This is the first reported work which applies FRET based
technique to determine Kd as well as classifying inhibitors of the LFA-1/ICAM-1 interaction.
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Introduction
The Leukocyte Function-associated Antigen-1 (LFA-1, also
known as CD11a/CD18, or aLb2), a member of the integrin
superfamily of cell surface adhesion molecules, is a heterodimeric
type I transmembrane glycoprotein consisting of one aL-subunit
(CD11a, 180 kD) and one b2-subunit (CD18, 95 kD) which are
non-covalently associated with each-other [1–3]. These two
subunits form an extracellular domain, which is further subdivided
into 13-subdomains, and two short cytoplasmic tails [4]. LFA-1 is
expressed exclusively on all leukocytes. The adhesion of leukocytes
with other cells is mediated through the interactions of LFA-1 with
its ligands, ICAM-1 (CD54) [5,6], ICAM-2 (CD102) [7], ICAM-3
(CD50) [8,9], ICAM-4 [10] or ICAM-5 (telencephalin) [11].
Among these, intercellular adhesion molecule-1 (ICAM-1), a
transmembrane glycoprotein of Ig supergene family, shows the
highest affinity towards LFA-1 [12]. It is composed of five
extracellular Ig-like domains (domains 1–5, D1–5), a transmem-
brane domain, and a short cytoplasmic domain [13,14]. Almost all
kinds of nucleated cells including endothelial cells, epithelial cells
and leukocytes express ICAM-1 [13]. Apart from LFA-1, ICAM-1
also serves as a receptor for another integrin Mac-1 [15], the
human rhinovirus [16], coxsackie A21 virus [17], and malaria
parasite Plasmodium falciparum [18].
ICAM-1 interacts with its counter receptor LFA-1 through the
binding of its first Ig-domain (D1) with the I- (inserted) domain on
the top of the N-terminus of aL subunit of LFA-1 [19]. More
specifically, the binding site of ICAM-1 is localized to a metal ion-
dependent adhesion site (MIDAS) motif of the aL subunit I-
domain of the integrin [20]. Binding of divalent cations, such as
Mg2+or Mn2+, to the MIDAS can activate LFA-1 and results in a
high affinity interaction with its receptor. These divalent cations
coordinate the five amino acids, Ser-139, Ser-141, Asp-237, Thr-
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206, and Asp-239, of the MIDAS and glutamate 34 in D1 of
ICAM-1 to form a cation coordination complex to facilitate the
LFA-1 and ICAM-1 interaction [21,22].
This molecular interaction of the activated LFA-1 with ICAM-1
plays an important role in many physiological processes such as in
the leukocyte-endothelial cell adhesion cascade, resulting in the
extravasation of leukocytes to the site of inflammation and the
formation of immunological synapse between leukocytes and an
antigen presenting cell (APC) [23,24]. However, the irregular
expressions of LFA-1 or ICAM-1 or both have also been related to
the specific pathologies of several autoimmune diseases such as
multiple sclerosis (MS), leukocyte adhesion deficiency (LAD),
thyroiditis, and insulin-dependent diabetes mellitus (IDDM)
[25,26]. For example, in MS, leukocytes show higher adhesion
capacity than normal; in addition, over expression of LFA-1 is also
observed, indicating that the LFA-1/ICAM-1 interaction may
play a role in the adhesion of leukocytes to brain microvascular
endothelial cells (MVEC) and ultimately in the disease pathology
[27]. Cell adhesion molecules also mediate in viral budding and
transfer. It has been demonstrated that high affinity form of LFA-1
facilitates viral entry and subsequently in the HIV syncytium
formation [28]. Moreover, the LFA-1/ICAM-1 interaction
induces the necessary cytokine release for the termination of
tumor growth while lymphocytes interact with tumor cells;
however, tumor cells with higher level of cell adhesion molecules
are observed to form metastatic lesions [29,30].
Based on these roles in several disease pathologies, the LFA-1/
ICAM-1 interaction can serve as a potential therapeutic target in
the development of new therapies for the autoimmune diseases,
metastasis cancer, and viral diseases. For example, anti-ICAM-1
and anti-LFA-1 were used in combination to inhibit the LFA-1/
ICAM-1 interaction to overcome the cardiac allograft rejection
[31]. Furthermore, several antibiotic therapies were developed for
the treatment of autoimmune diseases [32]. However, antibiotic
therapies have serious side effects in humans due to their large
molecular structure and nonhuman origin [33]. Thus, to
overcome these difficulties associated with antibiotic therapies,
small molecules, such as lovastatin, which specifically inhibits the
interaction of ICAM-1 with LFA-1 [34], were also developed. The
most important step towards developing inhibitory molecules to
the LFA-1/ICAM-1 interaction, however, was the use of short
peptides [35]. These peptides are capable of binding to the specific
sites of the target proteins and eventually can interfere with their
activity [36,37]. Hence, a better understanding of the structure,
function, and the mechanism of the interaction of ICAM-1 and
LFA-1 may further lead to novel therapeutic drug discoveries and
therapeutic tools.
Quantitative analysis of protein-protein interactions in vitro is of
fundamental importance in understanding these complex bio-
chemical processes. Among several methods that are available in
this context, Fo¨rster/Fluorescence resonance energy transfer
(FRET) technique has been widely used in vitro and in vivo to
study protein-protein interactions [38,39]. FRET is a highly
distant-dependent process where a fluorescent molecule (donor), in
its excited state, transfers energy non-radiatively to another
molecule (acceptor) through dipole-dipole interactions [40]. Since
FRET efficiency is proportional to 1/r6, where ‘‘r’’ is the distance
between the donor and acceptor, the FRET signal provides a high
degree of spatial sensitivity (between 1 and 10 nm) and signal
specificity; hence, it has been developed and well recognized as a
very powerful tool for the study of protein-protein interactions
[40]. Moreover, FRET is highly suitable for both spectroscopic
and imaging for static and real-time analysis. FRET has many
advantages over other current techniques used for quantitative
protein interaction studies, such as surface plasmon resonance
(SPR) [41], isothermal titration calorimetry (ITC) [42], or radio-
labled ligand binding assay [43]. In addition, FRET-based studies
also complement other single molecule fluorescence–based tech-
niques such as fluorescence correlation spectroscopy (FCS)
[44,45].
FRET measurements can be done in aqueous or solution phase,
similar to the environment in physiological conditions. Besides,
FRET measurements require only general fluorescence spectrom-
eters or microscopes compared to other mentioned methods which
need sophisticated instruments. Moreover, FRET measurements
do not require any special conjugation or orientation of the
proteins over other surfaces, other than conjugating the proteins
with fluorophores, which in general does not affect the protein
functional properties. Due to these advantages, quantitative FRET
assays have been developed to study protein-protein interactions
[46,47]. However, an earlier obstacle in successful development of
these assays was to extract the FRET emission signal at the
acceptor emission wavelength from a mixed emission spectrum
which contains the unquenched donor emission, direct acceptor
emission and the actual FRET emission signal. Recently, Song et
al. [48,49] developed a theoretical and experimental procedure to
overcome this obstacle and obtained the dissociation constant (Kd)
of the interaction between SUMO 1 and Ubc9. In this method,
correlation of donor and acceptor emissions were used to obtain
the absolute fluorescence signal contributions (due to unquenched
donor, direct acceptor and FRET emission signal) at the acceptor
emission wavelength in one single assay [49].
In this study, we have developed a steady-state ‘in-solution’
based quantitative FRET assay to determine the dissociation
constant (Kd) of the interaction between LFA-1 and ICAM-1. The
FRET emission signal was obtained from a single step process.
The interaction was studied using a chimeric molecule consisting
of the amino-terminal first two Ig domains of human ICAM-1
(D1-D2) fused to IgG1 Fc region (D1-D2-Fc) [50]. In our FRET
assay, Alexa Fluor 488-LFA-1 served as the donor, and Alexa
Fluor 555-D1-D2-Fc, the acceptor. Our results show that the
human recombinant D1-D2-Fc interacts with LFA-1 with a Kd of
17.9361.34 nM. Moreover, we used this LFA-1 and D1-D2-Fc
interaction to develop an ‘in-solution’ FRET based screening assay
to measure the inhibition (to the LFA-1/ICAM-1 interaction) of
LFA-1 derived short peptides (CD11a237–261, CD11a441–465, and
CD11a456–465) in terms of their inhibition efficiency, derived from
the corresponding FRET efficiency. In addition, we have
determined the optimal fluorophore to protein (F/P) ratios and
acceptor to donor (A/D) fluorophore ratios to develop the
screening platform to specifically detect the inhibitors of the
LFA-1/ICAM-1 interaction. The developed steady-state FRET
based assay can further be used to study the LFA-1/ICAM-1
interaction in several physiological conditions in vitro and also have
the potential to be developed into a high through-put screening
(HTS) assay to identify potential inhibitors to LFA-1/ICAM-1
interactions as well as for other protein-protein interactions.
Results and Discussion
In our FRET assay, the conjugated fluorophore-protein pair of
Alexa Fluor 488-LFA-1 served as the donor, while Alexa Fluor
555-D1-D2-Fc as the acceptor. Both fluorophores are amine-
reactive reagents which can react with non-protonated aliphatic
amine groups, including the amine terminus of proteins and the e-
amino groups of lysines. The scheme for FRET measurement is
illustrated in Fig. 1(a). The normalized absorption and emission
spectra for Alexa Fluor 488 and Alexa Fluor 555 were obtained to
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confirm the fluorescence properties of the fluorophores in our
experimental conditions [Fig. 1(b)].
Determining the fluorophore to protein (F/P) molar ratio
The fluorophore to protein (F/P) molar ratio was obtained for
each of the Alexa Fluor 488-LFA-1 and Alexa Fluor 555-D1-D2-
Fc conjugates. Based on the UV-visible absorption spectra for the
fluorophore-protein conjugates [Fig. 1(c)], the F/P molar ratios
were calculated to be 1.4860.09 and 3.1460.27 for Alexa Fluor
488-LFA-1 and Alexa Fluor 555-D1-D2-Fc, respectively.
The knowledge of F/P molar ratios was utilized to calculate the
actual concentrations of donors and acceptors in the solutions.
Moreover, the FRET efficiency is highly dependent on the F/P
ratio. In general, higher F/P ratio should enhance resonance
energy transfer due to the increase in the overlap integral; i.e. the
increase in the number of acceptors per donor increases the
effective acceptor extinction coefficient, which in turn proportion-
ally improves the effective overlap integral for single donor-
multiple acceptor complexes and vice-versa [40,51]. However,
high F/P ratio may also lead to concentration dependent
quenching, and consequently, low sensitivity. Moreover, in our
case the fluorophores were conjugated randomly to the proteins
through their binding with the primary amines. Hence, higher F/
P ratio may contribute to a significant background noise. On the
other hand, low F/P ratios will lead to very low signals which may
not be easy to differentiate from the background noise. Recent
theoretical and experimental studies have also indicated that
FRET efficiency can be significantly increased by optimizing the
F/P ratio, especially when the energy transfer takes place to
multiple acceptors [52,53]. Following these facts, we optimized the
conjugation protocol to obtain F/P ratios for our fluorophore-
protein conjugates to have strong FRET activity, and also for the
subsequent determination of the dissociation constant (Kd) of the
LFA-1/D1-D2-Fc interaction as well as in screening assay
development to classify inhibitors of the interaction.
Ascertaining the FRET activity
In developing our spectral FRET assay, LFA-1 and D1-D2-Fc
were covalently labelled with small organic molecule fluorophores,
Alexa Fluor 488 (lex = 488 nm; lem = 520 nm) and Alexa Fluor
555 (lex = 555 nm; lem = 570 nm), respectively. To ascertain the
FRET activity between the fluorophore-protein conjugates, the
Figure 1. Illustration of the FRET assay. (a) A schematic diagram illustrating the phenomena of FRET with Alexa Fluor 488 conjugated LFA-1 as
the donor and Alexa Fluor 555 conjugated D1-D2-Fc as the acceptor. When there is no binding between LFA-1 and D1-D2-Fc, excitation of donor at
470 nm leads to 520 emission peak only. However, when there is binding between LFA-1 and D1-D2-Fc, excitation at 470 nm leads to acceptor
emission at 570 nm, due to FRET. (b) Normalized absorbance and emission spectra of Alexa Fluor 488 and Alexa Fluor 555. (c) UV- visible absorption
spectra for fluorophore-protein conjugates (for the determination of the molecular concentration of fluorophores and proteins).
doi:10.1371/journal.pone.0102572.g001
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emission spectra of Alexa Fluor 488-LFA-1 (100 nM), Alexa Fluor
555-D1-D2-Fc (100 nM), the equimolar mixture of Alexa Fluor
488-LFA-1 and Alexa Fluor 555-D1-D2-Fc as well as the
equimolar mixtures of Alexa Fluor 488 and Alexa Fluor 555 were
obtained under 470 nm excitation and compared. Here, and in
the rest of this article, the concentration values represent the
concentration of the protein in the fluorophore-protein conjugate
solution, and not the fluorophore concentration. The key
parameters of the fluorescence multiplate reader set for these
measurements (to obtain the experimental results shown in Fig. 2)
are listed in Table S1. From Fig. 2 it is clearly observed that the
donor emission intensity is quenched around 520 nm; whereas an
increase in the acceptor emission is observed around 570 nm for
the fluorophore-protein conjugate mixture. This sensitized emis-
sion intensity of the acceptor is significantly higher than that
corresponding to the direct emission of Alexa Fluor 555-D1-D2-
Fc. These prominent spectral changes indicate the non-radiative
energy transfer between Alexa Fluor 488 and Alexa Fluor 555 in
the fluorophore-protein conjugate mixture and the binding
between LFA-1 and D1-D2-Fc. We noticed that the count rate
was very high for the donor alone (at 520 nm), in comparison with
the corresponding value for the acceptor alone (at 570 nm); this
can be attributed to the fact that the samples (i.e., the donor alone,
the acceptor alone, as well as the FRET mixture) were excited at
470 nm, which is the excitation maxima of donor. Moreover, the
large difference in the quantum yields of Alexa Fluor 488 (0.92)
and of Alexa Fluor 555 (0.10) [54] may also contribute to this
result.
Steady-state FRET binding assay to determine the
dissociation constant (Kd) of the interaction between
LFA-1 and D1-D2-Fc
In determining the equilibrium dissociation constant (Kd)
between the interacting protein pairs, LFA-1 and D1-D2-Fc, from
the FRET binding assay, several concentrations of the acceptor
conjugate, Alexa Fluor 555-D1-D2-Fc, were added to a fixed
concentration of the donor conjugate, Alexa Fluor 488-LFA-1.
The donor conjugate concentration was kept constant at 100 nM
while the acceptor conjugate concentration was varied from 0 upto
1.6 mM. These FRET mixtures, with different donor-to-acceptor
ratios, were excited by 470 and 530 nm. The fluorescence
emission spectra for the FRET assay, excited at 470 nm, are
shown in Fig. 3(a). Each spectrum shows two distinct peaks, one at
520 (due to unquenched Alexa Fluor 488, FD), and the other at
570 nm (FDA). The peak intensity at 570 nm has contributions
from unquenched donor emissions, direct acceptor emission and
the emission of acceptor due to FRET (FFRET). However, when
the FRET mixture was excited with 530 nm, only a single peak
corresponding to the direct emission of the acceptor (FA) was
observed.
Thus, to obtain the absolute maximum FRET emission signal at
570 nm (FFRETmax), we need to quantify each contribution from
the donor and acceptor emissions as well as the FRET emission
signal (FFRET). Fig. 3 [b] shows the donor emissions (FD) when the
FRET mixture was excited with 470 nm. It is clearly observed that
the direct emission of Alexa Fluor 488-LFA-1 decreased as the
concentrations of the Alexa Fluor 555-D1-D2-Fc was increased
from 0 upto 1.6 mM, as more donors were bound to the acceptors
when the concentration of the later was increased. However, the
emission at the 570 nm from the Alexa Fluor 555-D1-D2-Fc (FA)
increased steadily as the FRET mixture was excited with 530 nm
[Fig. 3(c)]. The total emission signal at 570 nm (FDA), when the
FRET mixture was excited at 470 nm, also increased with the
increase in the acceptor concentration [Fig. 3(d)].
In general, the direct emission of Alexa Fluor 488-LFA-1 at
570 nm is expected to be proportional to its emission at 520 nm
when excited at 470 nm. This proportionality factor was denoted
as ‘‘a’’ and defined as the ratio of the emission intensity at Alexa
Fluor 488-LFA-1 alone at 570 nm to that at 520 nm when excited
at 470 nm. To determine the ratio factor, ‘‘a’’, several concentra-
tions of Alexa Fluor 488-LFA-1 were prepared and their
corresponding emission spectra were obtained [Fig. 4(a)]. From
these spectra and following the definition, the value of ‘‘a’’ was
found to be 0.12960.015. Likewise, it is also logical to expect that
the direct emission of Alexa Fluor 555-D1-D2-Fc at 570 nm when
excited at 470 nm is proportional to its emission at 570 nm when
excited at 530 nm and this ratio factor was denoted as ‘‘b’’. To
obtain ‘‘b’’, a series of concentrations of Alexa Fluor 555-D1-D2-
Fc alone was prepared and their emission spectra were obtained
upon excitation at 530 [Fig. 4(b)] and 470 nm [Fig. 4(c)]. The
calculated value of ‘‘b’’ was 0.10160.008. Now, multiplying FD
with ‘‘a’’ and FA with ‘‘b’’ will give the actual direct emission
contribution of the donors and acceptors at 570 nm when the
FRET mixture is excited with 470 nm, which was used in the
subsequent determination of the dissociation constant.
Determination of the dissociation constant (Kd). The
quantitative values of the direct emission signal of Alexa Fluor
488-LFA-1 (FD), Alexa Fluor 555-D1-D2-Fc (FA) as well as total
emission signal (FDA) at 570 nm, when the FRET mixtures were
excited at 470 nm, along with a= 0.129 and b= 0.101 were used
in Eq. (4) (see ‘‘Materials and Methods’’) to obtain the FRET
emission signal (FFRET) at 570 nm for each concentrations of the
Alexa Fluor 555-D1-D2-Fc in our FRET binding assay [Fig. 3(a)].
To obtain the maximum FRET emission signal (FFRETmax) and the
dissociation constant (Kd), Eq. (6) (see ‘‘Materials and Methods’’),
derived from the nonlinear regression analysis, was used to fit the
data sets FFRET vs. Alexa Fluor 555- D1-D2-Fc concentrations as
shown in Fig. 5 (adj. R-square = 0.9895). From the analysis, the
value of FFRETmax was found to be 6.33610
3 RFU and that of Kd
was 17.9361.34 nM. This value of Kd is in good agreement with
that obtained by surface plasmon resonance spectroscopy (SPR)
reported by Wu et al. [55]. This method can further be utilized to
study the effects of various physiological conditions such as pH,
presence of divalent cations on the interaction of LFA-1 and
ICAM-1.
Developing the steady-state FRET based screening assay
Determining the optimal acceptor to donor fluorophore
(A/D) ratio. The acceptor to donor fluorophore (A/D) ratios
were determined using the F/P ratios and the amount of proteins
present in the mixture of Alexa Fluor 488-LFA-1 and Alexa Fluor
555-D1-D2-Fc. The optimal A/D ratio is very critical for
resonance energy transfer between the acceptor and the donor
for a FRET pair. Very high or very low amount of either
fluorophores may result in self-quenching and/or insignificant
radiative energy transfer. Due to these facts, the A/D ratio that
showed the highest energy transfer for our FRET pair of Alexa
Fluor 488 and Alexa Fluor 555 was used to develop the steady-
state FRET based screening assay to identify the inhibitors of
LFA-1 and D1-D2-Fc interaction.
To obtain the optimal A/D ratio for our FRET pair, the
concentration of the acceptor conjugate, Alexa Fluor 555-D1-D2-
Fc was kept constant at 100 nM and that of Alexa Fluor 488-LFA-
1 was varied: 25 nM (A/D = 8.40), 50 nM (A/D = 4.20), 100 nM
(A/D = 2.12), 150 nM (A/D = 1.41), 200 nM (A/D = 1.06),
250 nM (A/D = 0.84) and 300 nM (A/D = 0.70). The mixtures
were excited at 470 nm. The fluorescence emission spectra for all
the A/D ratios are shown in Fig. 6. For each A/D ratio, the FRET
Quantitative FRET Based Assay to Study LFA-1/ICAM-1 Interaction
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efficiency was also calculated using Eq. (3) (see ‘‘Materials and
Methods’’) to compare the FRET activity (Table 1). From this we
observed that the highest FRET efficiency was achieved at A/
D = 2.12) which was used for the subsequent development of our
FRET screening assay. This result can be understood from the
theoretical investigation by Bojarski et al. [52], which suggested
that the FRET efficiency can be significantly increased at a given
distance if the energy transfer takes place towards multiple
acceptors instead of a single acceptor molecule. Moreover, too
little or too much of either fluorophore can also significantly
reduce the FRET signals due to self-quenching and/or insufficient
energy transfer [56].
FRET screening assay. Inhibition of the receptor-ligand
interaction of LFA-1 and ICAM-1 by short peptide based
molecules have been demonstrated for the development of peptide
based drugs for diseases related to these interacting protein pairs.
In our study, we identified three LFA-1 derived peptides,
CD11a237–261, CD11a44–465, and CD11a456–465, to compare their
inhibition efficiency via our steady-state FRET based competitive
screening assay. Moreover, the inhibition efficiency of lovastatin, a
well-known potent inhibitor of the ICAM-1 interaction, was also
obtained to further validate the FRET screening platform.
Lovastatin belongs to naturally occurring drugs of Statins [34]
which has been widely used clinically to lower the serum
cholesterol levels [57]. Besides, it has also been shown that
lovastatin binds with the highly conserved I-domain of LFA-1
(CD11a I-domain) to inhibit the interaction of LFA-1 with its
counter ligand ICAM-1 [58], which leads to a reduction of human
immunodeficiency virus type 1 replication [59].
The inhibitory effect of lovastatin is summarized in Fig. 7(a).
The FRET efficiency of the FRET mixture, Alexa Fluor 488-LFA-
1 (100 nM) and Alexa Fluor 555-D1-D2-Fc (100 nM), was steadily
decreased upon incubations with increasing concentrations of the
lovastatin (Table S2). In the absence of inhibitors, the FRET
efficiency for the equimolar mixture of Alexa Fluor 488-LFA-1
and Alexa Fluor 555-D1-D2-Fc was found to be 53.51%. But with
Figure 2. Ascertaining the FRET activity between Alexa Fluor 488-LFA-1 and Alexa Fluor 555-D1-D2-Fc. Fluorescence emission spectra
of individual fluorophore-protein conjugates, Alexa Fluor 488-LFA-1 (100 nM) and Alexa Fluor 555-D1-D2-Fc (100 nM), and a mixture of Alexa Fluor
488-LFA-1 (100 nM) and Alexa Fluor 555-D1-D2-Fc (100 nM) are compared. A sensitized acceptor emission at 570 nm and a donor quenching at
520 nm are observed in the emission spectra of the FRET mixture, confirming FRET. For control, the emission spectrum of the mixture of the dyes
(Alexa Fluor 488+ Alexa Fluor 555), 100 nM each is also shown. That fact that no emission peak appeared at 570 nm for Alexa Fluor 555 when only
the dye mixture (Alexa Fluor 488+ Alexa Fluor 488) was excited at 470 nm, whereas a prominent acceptor sensitized peak was observed for the FRET
mixture (Alexa Fluor 488-LFA-1+ Alexa Fluor 555-D1-D2-Fc) indicates that the random FRET between the free dye molecules can be neglected in our
study. All the spectra were obtained under the excitation of 470 nm. The gain of the spectrofluorometer was set at 100 (manual). The excitation and
the emission bandwidths were fixed at 9 nm (for 316–850 nm excitation range) and 20 nm (for 280–850 nm emission range) for all the
measurements. The fluorescence emissions were recorded with an integration time of 20 ms (more details on Table S1).
doi:10.1371/journal.pone.0102572.g002
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increasing concentration of the lovastatin, the FRET efficiency
decreased to 5.3% for 200 mM of lovastatin. The inhibition






where Fcontrol is the FRET efficiency of the Alexa Fluor 488-LFA-1
and Alexa Fluor 555-D1-D2-Fc alone and Fx is that of the FRET
mixture when incubated with inhibitors. The inhibition efficiency
of lovastatin was calculated to be 69.4860.77%, 73.8460.56%,
84.9860.10%, and 90.0360.06% for 0.2, 2, 20, and 200 mM
respectively [Fig. 7(a)]. These results show that the FRET
screening assay is sensitive enough to quantify the concentration
dependent inhibition activity of inhibitors for the LFA-1 and D1-
D2-Fc interaction and can be further used to assess the inhibitors
in terms of their inhibition efficiency for the protein interactions of
interest.
To characterize and compare the inhibitory activity of the
selected peptides, CD11a237–261, CD11a441–465, and CD11a456–
465, the FRET mixture was incubated with several concentrations
(0.02, 0.2, 2, and 20 mM) of the peptides (following the procedure
described in the ‘‘Materials and Methods’’ section) and the FRET
efficiency (Tables S3, S4, S5) and the inhibition efficiency
[Fig. 7(b)] were calculated for each case. The inhibition efficiency
for CD11a237–261 at 0.02, 0.2, 2, and 20 mM are 40.8160.31%,
47.0560.56%, 53.1660.70%, 65.1360.81%, respectively; the
corresponding values for CD11a441–465, at the same concentra-
tions, are 20.8960.72%, 37.0860.29%, 46.9360.89%,
62.0160.15%, respectively; and for CD11a456–465, the corre-
sponding values are 12.1760.91%, 20.2660.69%, 36.4660.42%,
51.4160.33%. From these values, we note that the difference in
inhibition efficiency of these three peptides is much more
significant at low peptide concentration (on the order of 0.02 to
0.2 mM), the cause of which requires further investigation.
Nevertheless, in all cases, the inhibition efficiency of CD11a237–
261 is highest and CD11a456–465 the lowest, which are in good
agreement with those reported in the literature [36].
Figure 3. Determination of the FRET emission signal at 570 nm. (a) Fluorescence emission spectra (when excited at 470 nm) of Alexa Fluor
488-LFA-1 and Alexa Fluor 555-D1-D2-Fc mixtures, wherein the Alexa Fluor 488-LFA-1 concentration was fixed at 100 nM and that of Alexa Fluor 555-
D1-D2-Fc was varied from 0 to 1.6 mM; (b) Emission signal of the donor (FD) in the mixture at 520 nm when excited at 470 nm; (c) Emission signal of
Alexa Fluor 555 at 570 nm (FA) in the mixture when excited at 530 nm; (d) Total emission signal of the mixture at 570 nm when excited at 470 nm.
From (b), we see that the quenching of the donor is negligible when the acceptor concentration exceeds ,500 nM, which indicates that the
increased concentrations of acceptor gradually saturate the number of donor binding pairs.
doi:10.1371/journal.pone.0102572.g003
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Conclusions
A steady-state ‘in solution’ FRET binding assay has been
developed to obtain the dissociation constant (Kd) of the LFA-1/
ICAM-1 interaction using Alexa Fluor 488-LFA-1 as the donor
and Alexa Fluor 555-D1-D2-Fc as the acceptor. The dissociation
constant for the interaction was determined to be
17.9361.34 nM. Although the LFA-1/ICAM-1 interaction has
been studied extensively, to our knowledge, the application of ‘in
solution’ FRET to obtain the dissociation constant of this
interaction has not yet been reported. Our approach provides a
simple and efficient way to study not only the LFA-1/ICAM-1
interaction kinetics at different biochemical conditions relevant to
physiological environment, but also a wide variety of protein-
protein interactions in general.
Furthermore, we have also demonstrated a steady-state ‘in-
solution’ FRET based screening assay using the same donor and
acceptor pair to identify and assess short peptides in terms of their
inhibition efficiency to the LFA-1/ICAM-1 interaction. Specifi-
cally, we have shown that among the three LFA-1 derived
peptides, CD11a237–261, CD11a441–465, and CD11a456–465,
CD11a237–261 yields the highest inhibition efficiency, and
CD11a456–465 the lowest. This screening assay can be further
developed into a high throughput screening assay to obtain hits
from large peptide libraries for the development of potential




All the reagents were of reagent grade unless otherwise
specified. The protein, recombinant human integrin LFA-1
(aLb2), was purchased from R&D systems (Minneapolis, USA).
The human recombinant D1-D2-Fc was synthesized in our lab
(Instituto de Carboquı´mica ICB-CSIC, Zaragoza) in Spain (44).
LFA-1 derived peptides, CD11a237–261, CD11a441–465, and
CD11a456–465, were purchased from GenScript (Piscataway,
USA). The sequences of CD11a237–261, CD11a441–465, and
CD11a456–465 were ITDGEATDSGNIDAAKDIIR-YIIGI (LFA-
1a derived), GVDVDQDGETEL-IGAPLFYGEQRG (LFA-1a
derived), and APLFY- GEQRG (LFA-1a derived), respectively.
Mevinolin (synonym of Lovastatin) from Aspergillus species was
obtained from Sigma (Missouri, USA). The fluorophores, Alexa
Figure 4. Determination of the ratio constants, a and b. (a) To obtain a, fluorescence emission spectra of Alexa Fluor 488-LFA-1 alone at three
different concentrations (100, 200, and 300 nM), excited with 470 nm, were obtained. To calculate b, fluorescence emission spectra of Alexa Fluor
555-D1-D2-Fc only at several concentrations (100, 200, 300, 400, and 500 nM) upon excitation at 530 nm (b) and 470 nm (c) were obtained.
doi:10.1371/journal.pone.0102572.g004
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Fluor 488 carboxylic acid, succinimidyl ester and Alexa Fluor 555
carboxylic acid, succinimidyl ester, were procured from Molecular
Probes (Eugene, Oregon, USA). The organic solvent, dimethyl
sulfoxide (DMSO) dried, was obtained from Merck (Darmstadt,
Germany). The Slide-A-Lyzer dialysis cassette G2 (0.5 ml), used
for removing free dyes in labelling reactions and exchange of
buffer, was bought from Thermo Scientific (Rockford, USA). The
96-microwell transparent/black flat plates were obtained from BD
Biosciences (Bedford, MA, USA).
Methods
In the following sections, the conjugation protocol for the dyes
with proteins as well as the scheme of our FRET assay are
described in detail.
Preparation of Alexa Fluor 488- LFA-1 conjugate
The conjugation of Alexa Fluor 488 with LFA-1 was done by
following the protocols reported previously [60]. In short, LFA-1
was dissolved in freshly prepared phosphate buffered saline (PBS)
at a concentration of 1 mg/ml; 1 mg/ml of Alexa Fluor solution
was prepared in DMSO and used immediately. 10 ml of freshly
prepared 1 M sodium bicarbonate, pH 9.0, was added to 100 ml of
LFA-1 solution and mixed thoroughly. To this solution, 10 ml of
Alexa Fluor 488 solution was added and incubated for 2 hrs. in the
dark at room temperature under gentle shaking. After the
reaction, the free dyes were removed by exhaustive dialysis using
Slide-A-lyzer dialysis cassette G2 against PBS buffer, pH 7.4, and
left overnight at 4uC.
Preparation of Alexa Fluor 555-D1-D2-Fc conjugate
The protocol for labelling of Alexa Fluor 555 to D1-D2-Fc was
identical to the preparation of Alexa Fluor 488-LFA-1 conjugate,
except that the dye was replaced by Alexa Fluor 555 and the
starting concentration of D1-D2-Fc solution was 535 mg/ml in
PBS.
Determination of fluorophore to protein (F/P) molar ratio
and optimal acceptor to donor fluorophore (A/D) ratio
The fluorophore to protein (F/P) molar ratio, i.e., the ratio of
moles of fluorophores to moles of protein in the conjugate, was
obtained for each of the two conjugated fluorophore-protein pairs
from the known extinction coefficients of the fluorophore and the
following equation
Figure 5. Determination of dissociation constant (Kd) and maximum FRET emissions (FFRETmax) signal. The plot shows the fitting curve
of FRET emission signal with equation (6). The FFRETmax and the corresponding Kd of the LFA-1/D1-D2-Fc interaction were determined to be
6.336103 RFU and 17.9361.34 nM, respectively. The flattening of the FRET emission signal, when the acceptor concentration exceeds ,500 nM, can
be attributed to the fact that the increased acceptor concentration gradually saturates the number of donor binding pairs.
doi:10.1371/journal.pone.0102572.g005
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F
P
~ Amax|Dilution FactorEfluorophore| protein½  ð2Þ
where Amax is the absorbance of the fluorophore-protein conjugate
at the maximum absorbance wavelength (lmax) of the dye,
efluorophore is the molar extinction coefficient of the fluorophore
Figure 6. Determination of A/D ratio for optimal FRET between Alexa Fluor 488-LFA-1 and Alexa Fluor 555-D1-D2-Fc. Fluorescence
emission scans were obtained for the Alexa Fluor 488-LFA-1 and Alexa Fluor 555-D1-D2-Fc mixture, where the concentration of Alexa Fluor 555-D1-
D2-Fc was kept constant at 100 nM and that of Alexa Fluor 488-LFA-1 was varied: 25 nM (A/D=8.40), 50 nM (A/D=4.20), 100 nM (A/D=2.12),
150 nM (A/D= 1.41), 200 nM (A/D= 1.06), 250 nM (A/D= 0.84) and 300 nM (A/D= 0.70). The mixtures were excited at 470 nm. The highest FRET
efficiency (,53.51%) was obtained for A/D= 2.12. For both 4.20 and 8.40 A/D ratios, the donor peak intensity is very small compared to the acceptor
peak, while for 2.12 A/D ratio, the donor peak intensity is higher but not overwhelming the acceptor peak intensity. These higher emission counts at
4.20 and 8.40 A/D can be attributed to the direct emission of the acceptor as the acceptor concentration exceeds the saturating concentration
required to saturate the donor binding pairs.
doi:10.1371/journal.pone.0102572.g006
Table 1. A/D Ratio and FRET Efficiency (%).
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at lmax, and [protein] is the molar concentration of the protein. All
the absorption measurements were done using DU 800 spectro-
photometer (Beckman coulter, Fullerton, Germany).
The FRET efficiency can be adjusted by changing the
fluorophore to protein ratio; the optimal acceptor to donor
fluorophore (A/D) ratio was obtained following the procedure
Figure 7. A summary of the inhibitory effects (to the LFA-1/ICAM-1 interactions) of (a) lovastatin; and (b) LFA-1 derived peptides.
‘‘*’’ and ‘‘**’’ denote statistical significance with p,0.05 and p,0.005, respectively, from student t-test. NS: Not Significant. In (a), different
concentrations of lovastatin were added to the FRET mixture of Alexa Fluor 488- LFA-1 (100 nM) and Alexa Fluor 555-D1-D2-Fc (100 nM). The
inhibition efficiency of lovastatin increased from 69.4860.77% at 0.2 mM to 90.0360.06% at 200 mM. This result confirms that this FRET based
screening assay is capable of identifying/classifying inhibitors of the LFA-1/ICAM-1 interaction based on inhibition efficiency study. From (b), a
comparison of the inhibition efficiencies (to the LFA-1/ICAM-1 interactions) of three LFA-1 derived peptides CD11a237–261, CD11a441–465, and
CD11a456–465 indicates that CD11a237–261 exhibits the highest inhibition efficiency while CD11a456–465 the lowest for all the concentrations tested in
this study.
doi:10.1371/journal.pone.0102572.g007
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reported in the literature [56] with slight modification. In short,
A/D is defined as the number of the acceptor fluorophore
molecules to donor molecule in the interacting protein complex.
Several concentration ratios of Alexa Fluor 488-LFA-1 and Alexa
Fluor 555-D1-D2-Fc were incubated for 30 minutes at room
temperature and the FRET emission spectra were obtained via a
fluorescence multiplate reader, Tecan Infinite M200 pro (Ma¨n-
nedorf, Switzerland). For each concentration ratio, the concen-
tration of the acceptor conjugate, Alexa Fluor 555-D1-D2-Fc, was
kept constant. The optimal A/D ratio for the FRET pair was
selected by comparing the FRET efficiencies for different A/D
ratios. FRET activity has been discussed and quantified in
different ways in the literatures, including Bossis et al. [61],
Stankovic et al. [62], and Lackowicz [40]; however, these methods
did not take into account the correction factors for various cross-
talks involved in FRET efficiency calculations, and are only
suitable for the ideal one donor and one acceptor systems [63].
Due to these facts, we have used equation (3) [64,65] given below
for the FRET efficiency (E) calculation which incorporates the






here, (l470, l) denotes the numerical integral of the emission
spectrum between 560 and 610 nm when excited with 470 nm.
fDA, fA, and fD represent the emission spectra of the FRET
mixture, acceptor alone, and donor alone, respectively. The
absorbance values of donor and acceptor, at the excitation
maximum of Alexa Fluor 488 of 470 nm, is represented by AD and
AA, respectively. Following the definition of overlap integral
[40,51], it follows that increasing the acceptor concentration will
lead to an increase in the overall effective acceptor extinction
coefficient value; hence, if the spectra are normalized for various
concentrations, the overlap integral will remain the same. In this
article, the calculation was implemented assuming that there is a
change in the overlap integral with different F/P and the
(associated) different A/D ratios. The optimal A/D ratio was
used for the development of the FRET based screening platform
for the assessment of peptides and small molecules for their
inhibition efficiency of the LFA-1 and ICAM-1 interactions.
FRET measurement and dissociation constant (Kd)
determination
To develop the steady-state FRET assay to obtain the
dissociation constant (Kd), the Alexa Fluor 488-LFA-1 was first
diluted in PBS, pH 7.4, 1 mM EGTA and 2 mM Mg2+ for
30 minutes. In the FRET mixture of total volume 50 ml, the final
concentration of Alexa Fluor 488-LFA-1 was 100 nM and that of
Alexa Fluor 555-D1-D2-Fc was varied from 0 upto 1.6 mM. The
mixtures were transferred into a 96-well plate for high throughput
fluorescence emission measurements. The fluorescence emission
spectrum of each well was determined with a fluorescence multi-
well plate reader Infinite M200 pro (Tecan, Gro¨dig, Austria). The
emissions of the FRET mixture at 520 and 570 nm were measured
at the donor excitation wavelength of 470 nm, and the emission at
570 nm was measured at the acceptor excitation wavelength of
540 nm. The raw fluorescence emission signals were background-
corrected and averaged over three experiments at each specific
condition. Each datum point represents the mean (and the
associated rms) values of 9 repeated measurements with 3 samples
(3 measurements per sample).
In our FRET measurement, two excitation wavelengths of 470
and 530 nm were used to excite Alexa Fluor 488 and Alexa Fluor
555, respectively, in the FRET mixture. When the mixture was
excited with 470 nm, two distinct peaks, at 520 and 570 nm, were
observed in the FRET emission spectrum. The peak at 520 nm is
due to the unquenched Alexa Fluor 488 (FD). However, the
emission peak intensity at 570 nm (FDA) has several components.
The analysis of this typical FRET spectrum was done following the
procedure reported by Song et al. [49]. In brief, the emission
intensity at 570 nm consisted of the contributions from (i) the
emission of unquenched Alexa Fluor 488, (ii) the direct emission of
Alexa Fluor 555, and (iii) the emission of Alexa Fluor 555 due to
the non-radiative energy transfer from Alexa Fluor 488 (FFRET). As
expected, when the FRET mixture was excited at 540 nm, only a
distinct emission peak at 570 nm (FA) due to the direct emission of
Alexa Fluor 555 was observed. The resultant FRET emission
(FFRET) was calculated from the following relation,
FFRET~FDA{a FDð Þ{b FAð Þ ð4Þ
where ‘‘a’’ and ‘‘b’’ were defined as ratio factors. Here, the ratio
‘‘a’’ was defined as the ratio of the emission intensity of Alexa
Fluor 488 alone at 570 nm to that at 520 nm when excited at
470 nm, while the ratio ‘‘b’’ as the ratio of the emission intensity of
Alexa Fluor 555 alone at 570 nm when excited at 470 nm to the
intensity at 570 nm when excited at 540 nm. FFRET was calculated
for different acceptor to donor ratios and non-linear regression was
applied to fit the datasets of FFRET and several concentrations of
Alexa Fluor 555-D1-D2-Fc to obtain the maximum FRET
emissions (FFRETmax). This FFRETmax was eventually used to
obtain the dissociation constant (Kd) of the interaction between
D1-D2-Fc and LFA-1 via equation (5) given below, derived from




Song etal. [49] have reported a systematical methodology to
deduce Kd from steady-state FRET measurements. Following
their procedure and assuming one-to-one interaction between D1-















where ‘‘A’’ denotes the concentration of the acceptor, Alexa Fluor
555-D1-D2-Fc, which was varied from 0 to 1.6mM; ‘‘D’’ is the
total concentration of donor, Alexa Fluor 488-LFA-1, which was
kept fixed at 100 nM.
FRET screening assay development
In developing steady-state ‘in solution’ FRET based competition
assay to assess peptides and small molecules for their inhibition
efficiency of the interaction between LFA-1 and D1-D2-Fc, A/D
ratio that showed highest energy transfer was used. The donor,
Alexa Fluor 488-LFA-1, with a concentration corresponding to the
highest A/D ratio was mixed with each kind of LFA-1 derived
peptides (CD11a237–261, CD11a441–465, and CD11a456–465) in
PBS, pH 7.4, 1 mM EGTA and 2 mM Mg2+. These mixtures of
Alexa Fluor 488-LFA-1 and peptides were further incubated with
Alexa Fluor 555-D1-D2-Fc, the concentration of which was
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maintained to that of the acceptable A/D ratio, for 30 mins. in
dark environment. The total reaction volume for each specific
condition was maintained at 50 ml and measurements were done
in 96-well plate platform. The FRET efficiency (%) was calculated
for each condition for each peptide to compare their inhibition
efficiency. For negative control, the FRET efficiency (%) of the
mixture of Alexa Fluor 488-LFA-1 and Alexa Fluor 555-D1-D2-
Fc, in the absence of the inhibitors, was also obtained. Moreover,
as positive control, the FRET efficiency (%) of the aforementioned
mixture was obtained in the presence of lovastatin, a potent
inhibitor of D1-D2-Fc.
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